News | March 12, 2024
AbCellera and Biogen collaborate on neurological antibody therapy
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Acquisition of exclusive commercialization rights for European markets
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Cipla completes transfer of Generics Business Undertaking
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated
